Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis

Trial Identifier: D9480R00033
Sponsor: AstraZeneca
NCTID:: NCT04799067
Start Date: May 2021
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Chronic Kidney Diseases; Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, Beijing Beijing, China
China, Guangdong Guangzhou, Guangdong, China
China, Guangdong Shenzhen, Guangdong, China
China, Hebei Shijiazhuang, Hebei, China
China, Hubei Taihe, Hubei, China
China, Jiangxi Nanchang, Jiangxi, China
China, Liaoning Shenyang, Liaoning, China
China, Shanghai Shanghai, China, 2000127
China, Shanxi Taiyuan, Shanxi, China
China, Shanxi Yangquan, Shanxi, China
China, Zhejiang Ningbo, Zhejiang, China